Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
Event context and recent move in AtaiBeckley
AtaiBeckley (ATAI) has been drawing attention after recent trading, with the stock last closing at US$4.02 and showing mixed short term performance, including a slight decline over the past day and week, but gains over the past month.
See our latest analysis for AtaiBeckley.
While the 1 day and 7 day share price returns have slipped, the 90 day share price return of 12.46% and 1 year total shareholder return of 143.33% suggest momentum has been building over a longer window.
If you are weighing AtaiBeckley against other opportunities in high growth areas, it can help to widen the lens and see what else is moving across 32 healthcare AI stocks
With AtaiBeckley trading at US$4.02, a value score of 2, a very large discount to a US$14.00 analyst target and signs of longer term share price momentum, is there still a buying opportunity here, or is the market already pricing in future growth?
Preferred Price-to-Book Multiple of 7.4x: Is it justified?
On simple valuation checks, AtaiBeckley screens as expensive, with a P/B of 7.4x compared with a US Pharmaceuticals industry average of 2.3x and a peer average of 5.6x.
The P/B ratio compares the company’s market value to its book value. This can matter for early stage biopharma where current profits are limited and investors are effectively paying for the asset base and pipeline.
Given AtaiBeckley is currently unprofitable, the premium P/B suggests the market is willing to pay more per dollar of net assets than it does for many peers. This may reflect interest in its mental health treatment pipeline and revenue that is forecast to grow 79.92% per year.
Against the industry and peer benchmarks, the 7.4x P/B stands out as materially higher. This indicates that investors are pricing in stronger prospects than the average US Pharmaceuticals stock and the company’s immediate peer group.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-book of 7.4x (OVERVALUED)
However, the story can change quickly if key clinical trials disappoint or if ongoing losses of US$663.398 million limit flexibility to keep funding the pipeline on current terms.
Find out about the key risks to this AtaiBeckley narrative.
Another view on value: DCF versus the rich P/B
The P/B of 7.4x paints AtaiBeckley as expensive, but our DCF model points in a different direction. The stock is at US$4.02 compared with an estimated future cash flow value of US$6.01, implying it trades about 33% below that mark. Which signal do you trust more: price on assets or price on future cash flows?
Look into how the SWS DCF model arrives at its fair value.
ATAI Discounted Cash Flow as at May 2026
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out AtaiBeckley for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.
Next Steps
With mixed signals across valuation and sentiment, do you want to rely on headlines or your own read of the data? Take a closer look at both the upside and the concerns by reviewing the 2 key rewards and 4 important warning signs
Looking for more investment ideas?
If you stop with just one stock, you risk missing other opportunities that fit your goals, risk comfort and time horizon on Simply Wall Street.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ATAI.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com